Abstract: The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.
Type:
Grant
Filed:
November 9, 2005
Date of Patent:
November 16, 2010
Assignee:
Idera Pharmaceuticals, Inc.
Inventors:
Ekambar R. Kandimalla, Qiuyan Zhao, Dong Yu, Sudhir Agrawal
Abstract: The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.
Type:
Grant
Filed:
October 27, 2003
Date of Patent:
September 7, 2010
Assignee:
Idera Pharmaceuticals, Inc
Inventors:
Ekambar R. Kandimalla, Qiuyan Zhao, Dong Yu, Sudhir Agrawal
Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunostimulatory oligonucleotides according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
Abstract: The invention provides methods for modulating the immune response caused by CpG-containing oligonucleotides. The methods according to the invention enable both decreasing the immunostimulatory effect for antisense applications, as well as increasing the immunostimulatory effect for immunotherapy applications.
Abstract: The invention features a method of selectively killing a first microorganism. The method includes: (i) contacting the first microorganism with a second microorganism that has a microcidal compound; and (ii) allowing the first microorganism and the second microorganism to undergo fusion, whereby the microcidal compound is delivered into and kills the microorganism that forms following the fusion.
Type:
Grant
Filed:
April 16, 1999
Date of Patent:
August 27, 2002
Assignee:
Whitehead Institute for Biomedical Research
Abstract: The invention provides new methods for modulating specific CMI-inducing cytokines in vivo. Such new methods result in stimulation of the cytokines IL-6, IL-12 MIP-1&bgr; and MCP without substantially inducing undesired cytokines. The methods according to the invention are based upon administration of oligonucleotides containing particular structural motifs which lead to specific cytokine induction.
Abstract: Cosmetic compositions for topical use that comprise an exfoliating enzyme for use in removal of at least a portion of the dead skin cells from the outer layer of skin, in conjunction with one or more botanicals, the delivery of which to subsurface layers and cells thereof of the skin is enhanced by the presence of the exfoliating enzyme. These compositions, including gels, lotions, and creams, are gentle, non-irritating and enhance the penetration of biological additives into the subsurface skin layers relative to currently commercially available compositions.